Radiological report: Expectations of clinicians

PURPOSE Although there have been many publications on composing an accurate radiological report, they usually do not include an assessment of the clinicians expectations from a radiological report. In this study, we aimed to assess the clinicians' expectations and preferences in terms of radiology report style and content. MATERIALS AND METHODS A multiple-choice questionnaire, containing 19 questions, was formed. Two-hundreds clinicians, working either in a university hospital or a public hospital, were allocated into 4 groups which included equal number of clinicians from surgery and internal medicine departments. Questionnaire was applied to participants by face-to-face interview. Results were analyzed for each group using Pearson chi-square test. RESULTS No statistically significant difference was found among four groups except for the 16(th) question which was about the image format pertaining to the report (CD/DVD or negative film). It has been determined that clinicians preferred detailed, standardized radiological reports with complete sections (i.e., clinical information, technique, findings, conclusion, recommendations). CONCLUSION This study provided essential data for radiologists to write more effective reports

A Comparison of Ramipril and Bevacizumab to Mitigate Radiation-Induced Brain Necrosis: An Experimental Study

Background: Bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, is a new treatment approach for radionecrosis. In our study, we compared the prophylactic and therapeutic usage of a promising agent, ramipril (an angiotensin-converting enzyme inhibitor), with that of bevacizumab for reducing radiation-induced brain injury after high-dose stereotactic radiosurgery (SRS). Methods: A total of 60 Wistar rats were used. The rats were irradiated with a single dose of 50 Gy using a Leksell Gamma Knife device. Bevacizumab and ramipril were administered in the prophylactic protocol (starting the first day of SRS) and in the therapeutic protocol (starting the fourth week of SRS). Their usage was continued until 12 weeks, and the right frontal lobes of the rats were examined histologically (hematoxylin and eosin stain) and immunohistochemically (hypoxia-inducible factor [HIF]-1α, VEGF, and CD31 antibody expression). Results: The expression of VEGF, HIF-1α, and CD31 had significantly increased at 12 weeks after SRS compared with the control group. The addition of bevacizumab or ramipril to SRS significantly mitigated the histological severity of radiation injury and the expression of VEGF, HIF-1α, and CD31. However, the prophylactic use of bevacizumab and ramipril seemed to be more effective than therapeutic administration. Our results also revealed that the greatest benefit was achieved with the use of prophylactic administration of bevacizumab compared with other treatment protocols. Conclusions: Ramipril might be a promising agent for patients with radionecrosis. Clinical studies are required to investigate the effective and safe doses of ramipril, which is an inexpensive, well-tolerated drug that can cross the blood–brain barrier. © 2020 Elsevier Inc